Linezolid controlled-release - Inventia Healthcare

Drug Profile

Linezolid controlled-release - Inventia Healthcare

Alternative Names: Linezolid 1200mg SR Tablets; Ozolid SR

Latest Information Update: 26 Feb 2016

Price : $50

At a glance

  • Originator Inventia Healthcare
  • Developer Inventia Healthcare; Ipca Laboratories; Unichem Laboratories; Zuventus Healthcare
  • Class Acetamides; Antibacterials; Oxazolidinones; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Skin and soft tissue infections

Most Recent Events

  • 05 Aug 2013 Phase-III clinical trials in Skin and soft tissue infections in India (PO, controlled-release tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top